Circulating CARMN for acute myocardial infarction prognosis and its incremental effect when combined with conventional biomarkers
- 1Emergency Medicine Center, Affiliated Hospital of Guangdong Medical University
Abstract
Background: This study aims to explore the clinical value of lncRNA CARMN in acute myocardial infarction (AMI) patients.
Methods: The study subjects included 156 AMI patients and 59 healthy controls. The serum CARMN levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). The correlation between CARMN and myocardial injury markers, as well as cardiac ultrasound indicators by Pearson analysis. Kaplan–Meier and Cox regression were employed to screen out the independent influencing factors for MACE in AMI patients, and a nomogram was constructed.
Results: In patients with AMI, the serum CARMN level is decreased. CARMN level correlated with cTnI, CK-MB, Myo, LVEF. A total of 156 patients with AMI were enrolled and followed up for 6 months, among whom 60 patients experienced MACE. Lower CARMN levels were associated with a higher incidence of MACE. The AUC of the combined model for predicting MACE reaches 0.867, and the nomogram has good calibration and high clinical net benefit.
Conclusion: Serum CARMN combined with myocardial injury markers and ultrasound indicators, may help predict MACE risk in patients with AMI.
Related
- Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study
- Community-Level Wastewater Surveillance of Nicotine Biomarkers Tracks Cardiovascular Disease Burden and Myocardial Infarction
- Admission Endothelial Activation and Stress Index in Acute Myocardial Infarction: Incremental Value Beyond the GRACE Score and a Test of the Index Weights
- Interpretable machine learning analysis of immune-inflammatory biomarkers for predicting no-reflow in patients with acute myocardial infarction after percutaneous coronary intervention.
- Machine Learning Approach to Identify Gut Microbiota Biomarkers in Patients with ST-Elevation Myocardial Infarction Presenting Primary Ventricular Tachyarrhythmias
BibTeX
@article{chen2026circulating,
title = {{Circulating CARMN for acute myocardial infarction prognosis and its incremental effect when combined with conventional biomarkers}},
author = {Zhirui Chen and Jue Chen and Jieming Zhou and Zhenxing Yao},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1881009},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1881009/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Circulating CARMN for acute myocardial infarction prognosis and its incremental effect when combined with conventional biomarkers
AU - Zhirui Chen
AU - Jue Chen
AU - Jieming Zhou
AU - Zhenxing Yao
PY - 2026
DA - 2026/10/21
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1881009
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1881009/full
AB - Background: This study aims to explore the clinical value of lncRNA CARMN in acute myocardial infarction (AMI) patients. Methods: The study subjects included 156 AMI patients and 59 healthy controls. The serum CARMN levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). The correlation between CARMN and myocardial injury markers, as well as cardiac ultrasound indicators by Pearson analysis. Kaplan–Meier and Cox regression were employed to screen out the independent influencing factors for MACE in AMI patients, and a nomogram was constructed. Results: In patients with AMI, the serum CARMN level is decreased. CARMN level correlated with cTnI, CK-MB, Myo, LVEF. A total of 156 patients with AMI were enrolled and followed up for 6 months, among whom 60 patients experienced MACE. Lower CARMN levels were associated with a higher incidence of MACE. The AUC of the combined model for predicting MACE reaches 0.867, and the nomogram has good calibration and high clinical net benefit. Conclusion: Serum CARMN combined with myocardial injury markers and ultrasound indicators, may help predict MACE risk in patients with AMI.
SN - 2297-055X
ER -